Appendix 4C Quarterly & Company Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- Strategy for Phase II Clinical Trial of Monepantel
- Appendix 4D & Half Yearly Report and Accounts
- Notice of Allowance received from USA Patent OffIce
- Treatment of Canine Cancers
- SPP Shortfall Heaily Oversubscribed
Later from Neurizon Therapeutics
- Appendix 4C
- Appendix 4C - Quarterly
- Clinical Study with PPL-1 Initiated following Approval
- Important Discovery in Cancer Therapy
- Key Licence Provided by NewSouth Innovations
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics